VIA
ELVN icon

Virtus Investment Advisers’s Enliven Therapeutics ELVN Stock Holding History

Virtus Investment Advisers’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$360K Sell
7,093
-9,080
-56% -$385K 0.08% 336
2026
Q1 		$634K Buy
16,173
+395
+3% +$10.9K 0.17% 188
2025
Q4 		$243K Buy
15,778
+9,991
+173% +$199K 0.07% 342
2025
Q3 		$118K Buy
5,787
+1,004
+21% +$20.2K 0.03% 407
2025
Q2 		$95.9K Sell
4,783
-2,359
-33% -$44.7K 0.03% 350
2025
Q1 		$141K Buy
+7,142
New +$154K 0.04% 352

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Virtus Investment Advisers's ELVN Position: Q2 2026 in Review

Virtus Investment Advisers reduced its Enliven Therapeutics (ELVN) stake by 56% in Q2 2026, selling an estimated $385K and leaving 7,093 shares worth $360K. The position accounts for 0.08% of the portfolio, ranked #336.

Virtus Investment Advisers first reported a position in ELVN in Q1 2025 and has held it in 6 quarters since. The position peaked at $634K in Q1 2026. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Virtus Investment Advisers held 7,093 shares of Enliven Therapeutics worth $360K as of Q2 2026.
  • Virtus Investment Advisers sold 9,080 Enliven Therapeutics shares in Q2 2026, an estimated $385K.
  • Enliven Therapeutics made up 0.08% of Virtus Investment Advisers's portfolio in Q2 2026, its #336 holding.
  • Virtus Investment Advisers first reported a position in Enliven Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Virtus Investment Advisers's Enliven Therapeutics position peaked at $634K in Q1 2026.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.